A Study to Assess the Efficacy, Safety and Pharmacokinetics of EYU688 in Patients With Dengue Fever

Exclusion Criteria19

• Participants with any of abnormalities of clinical laboratory parameters.
• Usage of any anticoagulant drugs.
• Current significant medical conditions or illness that the investigator considers should exclude the participants, especially those that require continuation of other medications likely to have an interaction with the study drug.
• Pregnant or nursing (lactating) women.
• Clinical signs and symptoms for severe dengue according to Dengue Guideline (WHO 2009) at screening.
• Participants with any of the following abnormalities of clinical laboratory parameters at screening:
• Hemoglobin \<12.0 g/dL in males; \<11.0 g/dL in females
• Hematocrit \>52 % in males; \>46 % in females
• Absolute neutrophil count \<1500/μL
• Platelet count \<80,000/mm3
• Creatinine \>165 μmol/L in males; \>130 μmol/L in females
• Serum creatine kinase \> 600 U/L
• ALT, AST levels more than 1.5X upper limit of normal (ULN)
• Total bilirubin \>24 μmol/L
• Usage of PPIs (proton pump inhibitor) which could affect absorption of EYU688 due to stomach pH value increase up to 48 hours prior to screening.
• Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant, unless they are using highly effective methods of contraception during dosing and for 4 days after stopping of investigational drug.
• History or long-QT syndrome, or clinically significant ECG abnormalities, or any of the following ECG abnormalities at screening:
• QTcF \> 450 msec (males)
• QTcF \> 460 msec (females)